CoChat

The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up

Wijnen, Mark, Olsson, Daniel S, van den Heuvel-Eibrink, Marry M, Hammarstrand, Casper, Janssen, Joseph A M J L, van der Lely, Aart-Jan, Johannsson, Gudmundur, Neggers, Sebastian J C M M · 2018 · European Journal of Endocrinology
Cited by 59

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Objective: Patients with craniopharyngioma are at an increased risk for cardio- and cerebrovascular mortality. The metabolic syndrome (MetS) is an important cardiometabolic risk factor, but barely studied in patients with craniopharyngioma. We aimed to investigate the prevalence of and risk factors for the MetS and its components in patients with craniopharyngioma. Design: Cross-sectional study with retrospective data. Methods: We studied the prevalence of and risk factors for the MetS and its components in 110 Dutch (median age 47 years, range 18–92) and 68 Swedish (median age 50 years, range 20–81) patients with craniopharyngioma with ≥3 years of follow-up (90 females (51%); 83 patients with childhood-onset craniopharyngioma (47%); median follow-up after craniopharyngioma diagnosis 16 years (range 3–62)). In Dutch patients aged 30–70 years and Swedish patients aged 45–69 years, we examined the prevalence of the MetS and its components relative to the general population. Results: Sixty-nine (46%) of 149 patients with complete data demonstrated the MetS. Prevalence of the MetS was significantly higher in patients with craniopharyngioma compared with the general population (40% vs 26% (P < 0.05) for Dutch patients; 52% vs 15% (P < 0.05) for Swedish patients). Multivariable logistic regression analysis identified visual impairment as a borderline significant predictor of the MetS (OR 2.54, 95% CI 0.95–6.81;P = 0.06) after adjustment for glucocorticoid replacement therapy and follow-up duration. Age, female sex, tumor location, radiological hypothalamic damage,90 Yttrium brachytherapy, glucocorticoid replacement therapy and follow-up duration significantly predicted components of the MetS. Conclusions: Patients with craniopharyngioma are at an increased risk for the MetS, especially patients with visual impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-17-0387

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 59

Metadata

Authors
Wijnen, M., Olsson, D. S., van den Heuvel-Eibrink, M. M., Hammarstrand, C., Janssen, J. A. M. J. L., van der Lely, A.-J., Johannsson, G., & Neggers, S. J. C. M. M.
Venue
European Journal of Endocrinology
Published
2018-01
Volume
178
Issue
1
Pages
11-22
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2753779505
Cited by
59
References
10
FWCI
3.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. https://app.cochat.ai/papers/10.1530/eje-17-0387
The paper
Wijnen, M., Olsson, D. S., van den Heuvel-Eibrink, M. M., Hammarstrand, C., Janssen, J. A. M. J. L., van der Lely, A.-J., Johannsson, G., & Neggers, S. J. C. M. M. (2018). The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. European Journal of Endocrinology. https://doi.org/10.1530/eje-17-0387

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.